A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
Completed
Conditions studied: Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
In brief
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
Key facts
- Study ID
- NCT06507852
- Run by
- Novartis
- People needed
- 95
- Starts
- 2022-10-03
- Expected to finish
- 2023-07-06
- Last updated by the study team
- 2024-07-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who were 18 years or older.
- Signed informed consent was obtained.
- Patients who received at least one inclisiran injection in the identification period.
- Patients with at least one diagnosis of ASCVD, ASCVD-RE or FH diagnosis prior to index date.
- Patients with at least one low-density lipoprotein cholesterol (LDL-C) measurement of 70 milligrams per deciliter (mg/dL) or greater, within 6 months prior to index date.
- ASCVD was defined as previous diagnosis of coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD).
- ASCVD-RE was defined as: no previous diagnosis of ASCVD at any time on the patient chart and they met at least one of the following criteria:
- Diagnosis of type II diabetes mellitus (T2DM).
- Diagnosis of type I diabetes mellitus (T1DM) of long duration (greater than 20 years).
- 10-year risk of 20% or greater by Framingham risk score.
You may not qualify if…
- None.
Where it is running
- Novartis — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.